Nu.Q® NETs: New sepsis study at Guy’s & St Thomas NHS Foundation Trust.

In December 2023, we had an exciting development regarding our Nu.Q^® NETs pillar. Guy’s & St Thomas’ NHS Foundation Trust, a leading UK hospital, announced the start of a 500-patient prospective study– EPICTETUS. The trial will involve using our Nu.Q^® NETs blood test to diagnose and monitor patients at risk of sepsis.

The announcement was featured as an exclusive, front-page story in the Sunday Times, and has been covered extensively in UK media outlets including ITV News, The Independent, Daily Mirror, and Daily Mail.

The piece includes a quote from Dr. Ron Daniels, founder and chief executive officer of the UK Sepsis Trust who said:“Delays in diagnosis result not only in lives lost, and not only in increased cost of care, but also in poor outcomes for survivors, including disability. If this research demonstrates that NET proteins fulfill their promise as a risk stratification tool, then lives will be saved.”

You can find more information about Nu.Q^® NETs here.